Stem cell therapy in retinal diseases?

Siqueira, Rubens Camargo

doi:10.5581/1516-8484.20120054

Cited by 6 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional sources of funding are Lamba et al [1] promoted the formation of RPC, and generated photoreceptors from hESC in a culture with supplementation of IGF1, noggin (inhibitor of BMP pathway) and Wnt inhibition [1,10,16] . Reynolds et al [1] , in 2009, implanted photoreceptor derived from hESC, with the objective of testing hESC to photoreceptor replacement in an animal model.…”

Section: Resultsmentioning

confidence: 99%

“…The introduction of the concept of SC therapy, after bombings in Hiroshima and Nagasaki, discovered that bone marrow (BM) transplanted into irradiated animals produced hematopoiesis. Hematopoietic SC (HSC) were identified in 1961, and their ability to migrate and differentiate into multiple cell types was documented [8][9][10] . SC transplants may be xenogenic (from another species), allogenic (from another individual) or autograft (from the same individual) [2,4] .…”

Section: Stem Cells and Cell Replacementmentioning

confidence: 99%

See 1 more Smart Citation

Stem cell therapy for retinal diseases

Garcia

Mendonça

Brant

et al. 2015

WJSC

View full text Add to dashboard Cite

In this review, we discuss about current knowledge about stem cell (SC) therapy in the treatment of retinal degeneration. Both human embryonic stem cell and induced pluripotent stem cell has been growth in culture for a long time, and started to be explored in the treatment of blinding conditions. The Food and Drug Administration, recently, has granted clinical trials using SC retinal therapy to treat complex disorders, as Stargardt's dystrophy, and patients with geographic atrophy, providing good outcomes. This study's intent is to overview the critical regeneration of the subretinal anatomy through retinal pigment epithelium transplantation, with the goal of reestablish important pathways from the retina to the occipital cortex of the brain, as well as the differentiation from pluripotent quiescent SC to adult retina, and its relationship with a primary retinal injury, different techniques of transplantation, management of immune rejection and tumorigenicity, its potential application in improving patients' vision, and, finally, approaching future directions and challenges for the treatment of several conditions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Stem Cells and Cell Replacementmentioning

confidence: 99%

Stem cell therapy for retinal diseases

Garcia

Mendonça

Brant

et al. 2015

WJSC

View full text Add to dashboard Cite

show abstract

“…In the present study, the autologous BM-MSCs were selected. Since the MSCs exhibit the lower potential of differentiation compared to RPCs, ESCs, and iPSCs, this stem cell type has a lower risk of differentiating into undesired tissues, teratoma formation, immune rejection (even from allogeneic sources), and ethical concerns to its use [ 20 , 21 ]. More importantly, many studies demonstrated the promising potential of the MSCs for retinal disease therapy.…”

Section: Discussionmentioning

confidence: 99%

“…Among other hypotheses, the paracrine effects, including tissue regeneration and immunomodulatory factors, are well-accepted benefits of the MSCs [ 7 , 8 , 22 ]. Theoretically, these secreted soluble factors could slow the degeneration of the neuroretinal cells with the possibility of restoring their functions [ 20 ]. More recently, the stem cell-free approach using the secretory components from MSCs, including the soluble mediators and extracellular vesicles (exosomes and microvesicles), are under investigation [ 9 , 23 ].…”

Section: Discussionmentioning

confidence: 99%

Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa

et al. 2021

View full text Add to dashboard Cite

Background Retinitis pigmentosa (RP) is a progressive inherited retinal disease with great interest for finding effective treatment modalities. Stem cell-based therapy is one of the promising candidates. We aimed to investigate the safety, feasibility, and short-term efficacy of intravitreal injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in participants with advanced stage RP. Methods This non-randomized phase I clinical trial enrolled 14 participants, categorized into three groups based on a single dose intravitreal BM-MSC injection of 1 × 106, 5 × 106, or 1 × 107 cells. We evaluated signs of inflammation and other adverse events (AEs). We also assessed the best corrected visual acuity (BCVA), visual field (VF), central subfield thickness (CST), and subjective experiences. Results During the 12-month period, we noticed several mild and transient AEs. Interestingly, we found statistically significant improvements in the BCVA compared to baseline, although they returned to the baseline at 12 months. The VF and CST were stable, indicating no remarkable disease progression. We followed 12 participants beyond the study period, ranging from 1.5 to 7 years, and observed one severe but manageable AE at year 3. Conclusion Intravitreal injection of BM-MSCs appears to be safe and potentially effective. All adverse events during the 12-month period required observation without any intervention. For the long-term follow-up, only one participant needed surgical treatment for a serious adverse event and the vision was restored. An enrollment of larger number of participants with less advanced RP and long-term follow-up is required to evaluate the safety and efficacy of this intervention. Trial registration ClinicalTrials.gov, NCT01531348. Registered on February 10, 2012

show abstract

“…Intravitreal delivery of BM-MNCs induced a slight improvement in visual function among advanced degenerative retinopathy patients, likely via a trophic effect on the vascular bed [120,121]. Similarly, CD34+ BM-HSCs, shown to incorporate within the retinal vasculature and release trophic factors in an ischemic eye mouse model [122], are being evaluated in clinical trials for treatment of RPE diseases.…”

Section: Retinal Pigmented Epithelium Degenerative Diseasesmentioning

confidence: 97%

Cell-Based Therapy Approaches: The Hope for Incurable Diseases

Buzhor¹,

Leshansky²,

Blumenthal³

et al. 2014

Regen. Med.

145

105

View full text Add to dashboard Cite

Cell therapies aim to repair the mechanisms underlying disease initiation and progression, achieved through trophic effect or by cell replacement. Multiple cell types can be utilized in such therapies, including stem, progenitor or primary cells. This review covers the current state of cell therapies designed for the prominent disorders, including cardiovascular, neurological (Parkinson's disease, amyotrophic lateral sclerosis, stroke, spinal cord injury), autoimmune (Type 1 diabetes, multiple sclerosis, Crohn's disease), ophthalmologic, renal, liver and skeletal (osteoarthritis) diseases. Various cell therapies have reached advanced clinical trial phases with potential marketing approvals in the near future, many of which are based on mesenchymal stem cells. Advances in pluripotent stem cell research hold great promise for regenerative medicine. The information presented in this review is based on the analysis of the cell therapy collection detailed in LifeMap Discovery(®) (LifeMap Sciences Inc., USA) the database of embryonic development, stem cell research and regenerative medicine.

show abstract

Stem cell therapy in retinal diseases?

Cited by 6 publications

References 40 publications

Stem cell therapy for retinal diseases

Stem cell therapy for retinal diseases

Intravitreal autologous mesenchymal stem cell transplantation: a non-randomized phase I clinical trial in patients with retinitis pigmentosa

Cell-Based Therapy Approaches: The Hope for Incurable Diseases

Contact Info

Product

Resources

About